STAT3 and hepatocellular carcinoma: Sorafenib combined with the triterpenoid cucurbitacin from Cucurbitaceae enhanced apoptosis in HepG2 and Huh7 human hepatocellular carcinoma cells by inhibiting STAT3 activity [83].